

1 **Title page**

2 **Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized**  
3 **patients with 2019 novel coronavirus pneumonia (NCP)**

4 Suxin Wan, M.D.<sup>1,2, #</sup>, Qingjie Yi, M.D.<sup>1, 3, #</sup>, Shibing Fan, Ph.D <sup>1, 4, #</sup>, Jinglong Lv, M.D.<sup>1,5, \*</sup>,  
5 Xianxiang Zhang, M.D.<sup>1,6</sup>, Lian Guo, M.D.<sup>1,6</sup>, Chunhui Lang, Ph.D <sup>1,7</sup>, Qing Xiao, M.D.<sup>8</sup>, Kaihu  
6 Xiao, M.D.<sup>1,9</sup>, Zhengjun Yi, Ph.D <sup>10</sup>, Mao Qiang, M.S. <sup>11</sup>, Jianglin Xiang, M.S. <sup>1,12</sup>, Bangshuo Zhang,  
7 M.D.<sup>1, 5</sup>, Yongping Chen, M.S.<sup>1, 5</sup>

8 <sup>1</sup> Chongqing University Three Gorges Hospital, Chongqing 404100, China;

9 <sup>2</sup> Pharmaceutical Department of Chongqing Three Gorges Central Hospital, Chongqing 404100,  
10 China;

11 <sup>3</sup> Quality control Department of Chongqing Three Gorges Central Hospital, Chongqing 404100,  
12 China;

13 <sup>4</sup> Neurosurgery of Chongqing Three Gorges Central Hospital, Chongqing 404100, China;

14 <sup>5</sup> Department of Hematology, Chongqing Three Gorges Central Hospital, Chongqing 404100, China;

15 <sup>6</sup> Department of Endocrinology, Chongqing Three Gorges Central Hospital, Chongqing 404100,  
16 China;

17 <sup>7</sup> Research and Foreign Affairs Department of Chongqing Three Gorges Central Hospital,  
18 Chongqing 404100, China;

19 <sup>8</sup> Department of Hematology, the First Affiliated Hospital of Chongqing Medical University,  
20 Chongqing 404016, China;

21 <sup>9</sup> Department of Cardiology, Chongqing Three Gorges Center Hospital, Chongqing 404100, China;

22 <sup>10</sup> School of mathematics and statistics, Chongqing University, Chongqing 401331, China;

23 <sup>11</sup> Basic College of Qingdao University, Qingdao, Shandong 266071, China;

24 <sup>12</sup> Department of Infectious Diseases, Chongqing Three Gorges Center Hospital, Chongqing 404100,  
25 China.

26 **\*Corresponding Author:** Jinglong Lv, Department of Hematology, Chongqing Three Gorges  
27 Central Hospital, No. 165, Xincheng Road, Wanzhou District, Chongqing 404100, China.

28 Tel: +86 023-58103232; E-mail: 13608388377@163.com

29

30 # **Suxin Wan, Qingjie Yi and Shibing Fan** contributed equally to this article.

31

32 **Running title:** Lymphocyte subsets and cytokines in peripheral blood of NCIP patients

33

34

35 **Abstract**

36 **Background:** To explore the cellular immunity and cytokines status of NCP patients and to predict  
37 the correlation between the cellular immunity levels, cytokines and the severity of patients.

38 **Methods:** 123 NCP patients were divided into mild and severe groups. Peripheral blood was  
39 collected, lymphocyte subsets and cytokines were detected. Correlation analysis was performed on  
40 the lymphocyte subsets and cytokines, and the differences between the indexes of the two groups  
41 were analyzed.

42 **Results:** 102 mild and 21 severe patients were included. Lymphocyte subsets were reduced in two  
43 groups. The proportion of CD8 + T reduction in the mild and severe group was 28.43% and 61.9%,  
44 respectively; The proportion of B cell reduction was 25.49% and 28.57%; The proportion of NK  
45 cell reduction was 34.31% and 47.62%; The detection value of IL-6 was 0 in 55.88% of the mild  
46 group, mild group has a significantly lower proportion of patients with IL-6 higher than normal than  
47 severe group; There was no significant linear correlation between the lymphocyte subsets and  
48 cytokines, while significant differences were noticed between the two groups in CD4 + T, CD8 + T,  
49 IL-6 and IL-10.

50 **Conclusions:** Low levels of CD4+T and CD8+T are common in severe NCP. IL-6 and IL-10 levels  
51 were higher in severe patients. T cell subsets and cytokines can be used as one of the basis for  
52 predicting the transition from mild to severe. Large number of samples are still needed to confirm  
53 the "warning value" of CD4 + T, CD8 + T IL-6 and IL-10.

54 **Key words:** 2019 novel coronavirus; lymphocyte subsets; cytokines; mild; severe

55

## 56 **Introduction**

57 2019-novel coronavirus (2019-nCoV), which was discovered due to viral pneumonia cases in  
58 Wuhan in 2019, was named by the World Health Organization (WHO) on 10 January 2020. The  
59 main source of infection is pneumonia patients infected by new coronavirus. Respiratory droplets  
60 are the main route of transmission and it can also be transmitted through contact. People are  
61 generally susceptible. At present, the occurrence, development, mechanism of prognosis and  
62 immune status of patients with 2019-nCoV are still unclear.<sup>1</sup> This study intends to detect the  
63 peripheral blood lymphocyte subsets and cytokines in 123 patients with 2019-nCoV infection by  
64 using four-color immunoflow cytometry and multiple microsphere flow immunofluorescence to  
65 investigate the cellular immunity status and cytokine levels of 2019-nCoV infected patients, to  
66 explore the correlation between cellular immune statuses, cytokine levels and the severity of 2019-  
67 nCoV infection.

## 68 **Materials and Methods**

### 69 *Patients*

70 From January 26, 2019 to February 4, 2020, 123 inpatients diagnosed with 2019- nCoV  
71 infection were collected in the Chongqing Three Gorges Central Hospital. All patients were  
72 confirmed to be positive for new coronavirus nucleic acid by real-time fluorescent RT-PCR. Patients  
73 were diagnosed according to the World Health Organization interim guidance for NCP and divided  
74 into mild and severe (including severe and critical) groups

### 75 *Blood sampling*

76 Blood samples of the patients were collected by the nurse according to the doctor's order, and  
77 all patients were not treated before the blood sampling or did not receive the standardized treatment  
78 according to the diagnosis and treatment scheme of NCP.

### 79 *Lymphocyte subsets detection*

80 Two test tubes were taken for each patient, and were numbered A and B respectively. 5  $\mu$ L of  
81 CD3/ CD8/ CD45/ CD4 antibody (Beijing Tongshengshidai Biotechnology Co., Ltd) was added to  
82 the tube A and 5  $\mu$ L of CD16 + 56/ CD45/ CD19 antibody was added to tube B. After adding 50  $\mu$ L  
83 of EDTA anticoagulant whole blood to each tube, the tubes were vortexed and kept at room  
84 temperature for 15 minutes in the dark. Then the samples were detected by four-color fluorescence  
85 labeled flow cytometry (Mindray BriCyte E6; Mindray, Shenzhen, China).

## 86 ***Cytokine detection***

87 The detection reagent of cytokine was provided by Qingdao Raisecare Biotechnology Co., Ltd  
88 (calibrator lot number: 20190801). Six cytokines including IL-4, IL-6, IL-10, IL-17, TNF and IFN  
89 were detected by multiple microsphere flow immunofluorescence according to the manufacturer's  
90 instructions. After the blood sample and the corresponding flow tube be numbered 101, 102, 103,  
91 104, and 105, EDTA-K2 anticoagulant whole blood was centrifuged at 2365 r / min for 30 min.  
92 Then 25  $\mu$ L of experimental buffer, 25  $\mu$ L of centrifuged plasma, 25  $\mu$ L of capture microsphere  
93 antibody, and 25  $\mu$ L of detection antibody were added to the corresponding flow tube. After  
94 incubating at room temperature for 2 hours in the dark with gentle shaking, 25  $\mu$ L SA-PE was added  
95 into the flow tube respectively, and then incubation was continued for 30 minutes. Subsequently,  
96 the diluted wash buffer (1:10) was added to the flow tube. After a few seconds of vortex shaking,  
97 the flow tube was centrifuged at 1500r / min for 5 minutes, the liquid was slowly poured out, and  
98 the flow tube was inverted on the absorbent paper. Then 100  $\mu$ L of diluted washing buffer (1:10)  
99 was added to the flow tube according to the requirements of the flow cytometer, and the test was  
100 performed after shaking for 10 seconds.

## 101 ***Statistical analysis***

102 All statistical analyses were performed using SPSS 22.0 (SPSS Inc., Chicago, IL, USA).  
103 Descriptive analyses were performed for categorical variables such as gender. Continuous variables  
104 such as inspection results were expressed as  $\bar{x} \pm s$  and compared using the independent samples t-  
105 test. Correlation analysis results were expressed by Pearson correlation coefficient and a larger  $r^2$   
106 indicates better linear correlation.  $P < 0.05$  was considered as statistically significant.

## 107 ***Ethics approval***

108 This study was approved by the ethical committee of Chongqing Three Gorges Central  
109 Hospital and informed consent was obtained from each patient.

## 110 **Results**

### 111 ***Baseline data***

112 The study population included 138 hospitalized patients with confirmed NCP. 102 NCP  
113 patients (55 males and 47 females) with a mean age of  $43.05 \pm 13.12$  (15~82) years in the mild  
114 group and 21 NCP patients (11 males and 10 females) with a mean age of  $61.29 \pm 15.55$  (34~79)  
115 years in the severe group were enrolled.

116 ***Lymphocyte subsets in peripheral blood of NCP patients***

117 According to the results of each index, CD4 + T, CD8 + T, B cell, NK cell, CD4 + T / CD8 +  
118 T were divided into below normal value, within normal value and above normal value. The  
119 corresponding quantities and proportions were respectively calculated, and the results were shown  
120 in **Table 1**.

121 Among the mild patients, 54 (52.90%) patients had CD4 + T below normal values, 48 (47.10%)  
122 were within normal values; 73 (71.60%) patients had CD8 + T within normal values, and 29 (28.40%)  
123 were lower than normal; 26 (25.49%) patients had B cell lower than normal, 75 (73.50%) were  
124 within normal, 1 (0.01%) was higher than normal; 35 (34.31%) patients had NK cell below normal  
125 values, 66 cases (64.71%) were within normal values, 1 case (0.01%) was higher than normal values;  
126 95 patients (93.14%) had CD4 + T / CD8 + T within normal values, 3 cases (2.94%) were lower  
127 than normal, 4 cases (3.92%) were higher than normal values.

128 In severe patients, CD4 + T was lower than normal in 20 patients (95.24%), within normal in  
129 1 patient (4.76%); CD8 + T was lower than normal in 13 patients (61.90%), within normal in 8  
130 patients (38.10%); B cell was lower than normal in 6 patients (28.57%), within normal in 15 patients  
131 (71.43%); NK cell was lower than normal in 10 patients (47.62%), and within normal in 11 patients  
132 (52.10%) 38%, 18 (85.71%) patients had CD4 + / CD8 + ratio within the normal value, 2 (9.53%)  
133 patients were lower than the normal value, 1 (4.76%) was higher than the normal value.

134 ***Cytokines in peripheral blood of NCP patients***

135 IL-4, IL-6, IL-10, IL-17, TNF, and IFN were divided into values of 0, within the normal value  
136 (normal values other than 0), and above the normal value according to the results of various  
137 indicators. The corresponding quantities and proportions were counted (**Table 2**).

138 Among the mild patients, 102 (100%) patients had IL-4, IL-10, and IL-17 all within normal  
139 values; 57 (55.88%) patients had IL-6 values of 0 and 14 (13.73%) within normal values, 31  
140 (30.39%) were higher than normal; 100 (98.04%) patients had TNF values within normal values, 2  
141 (1.96%) were higher than normal values; 92 (90.20%) patients had IFN within the normal values, 5  
142 cases (4.90%) had IFN values of 0, and 5 cases (4.90%) were higher than normal values.

143 In severe patients, IL-4, IL-10, IL-17 and TNF were all within the normal values in 21 (100%)  
144 patients; IL-6 was 0 in 3 patients (14.29%), 2 patients (9.52%) were within the normal values, 16  
145 patients (76.19%) were higher than the normal values; IFN was within the normal values in 20

146 patients (95.24%), and 1 patient (4.76%) was higher than the normal values.

#### 147 *Correlation between lymphocyte subsets and IL-6 in NCP patients*

148 Considering that the value of IL-6 changed most in the mild and severe groups, the correlation  
149 between the lymphocyte subsets and the cytokine IL-6 was analyzed. The data with IL-6 value of 0  
150 in each group (57 cases in light group and 3 cases in severe group) were excluded, and 45 cases in  
151 the mild group and 18 cases in severe group were included in the correlation analysis. As shown in  
152 **Table 3**, the correlation analysis between IL-6 and lymphocyte subsets showed that the Pearson  
153 correlation coefficients of IL-6 and CD4 + T, CD8 + T, B cell, NK cell, CD4 + T / CD8 + T were  
154 very low, and there was no significant linear correlation.

#### 155 *Comparison of lymphocyte subsets and cytokines in peripheral blood between patients with mild* 156 *and severe NCP*

157 The data (57 cases of IL-6 and 3 cases of IFN in the mild group) with the index value of 0 in  
158 the two groups were excluded. Two independent-samples t test was performed on the lymphocyte  
159 subsets and cytokines of the mild group and the severe group, with  $\alpha=0.05$  as the inspection level.  
160 Significant differences were observed in CD4 + T, CD8 + T, IL-6, IL-10 between the mild group  
161 and the severe group ( $P < 0.05$ ), while no significant difference was detected in B cell, NK cell,  
162 CD4 + T / CD8 + T, IL-4, IL-17, TNF, IFN between the two groups ( $P > 0.05$ , **Table 4**).

#### 163 **Discussion**

164 Lymphocyte subsets play an important role in the body's cellular immune regulation, and each  
165 cell restricts and regulates each other. This study found that among NCP patients, the reduction rate  
166 of CD4 + T accounted for 52.90% in the mild group, and 95.24% in the severe group; the reduction  
167 rate of CD8 + T accounted for 28.40% in the mild group, and 61.90% in the severe group, indicating  
168 that T lymphocytes were more inhibited in severe patients when the body is resistant to 2019-nCoV  
169 infection. This was consistent with the research conclusions of Huabiao Chen<sup>2</sup> in SARS coronavirus,  
170 revealing that the body responds in the same way when coping with homologous coronavirus  
171 infection. The reduction ratio of B cell was 25.49% and 28.57% in the mild group and the severe  
172 group, respectively, with no significant difference. The reduction ratio of NK cells accounted for  
173 34.31% in the mild group and 47.62% in the severe group, which suggested that 2019-nCoV  
174 infection limited the activity of NK cells to a certain extent, and in view of the fact that immune  
175 adjuvant IL-2 can improve the activity of NK cells, the above research results may provide new

176 ideas and evidence for clinical treatment.<sup>3</sup>

177 Chaolin Huang et al.<sup>4</sup> showed that the levels of IL-2, IL-7, IL-10, TNF- $\alpha$ , G-CSF, IP-10, MCP-  
178 1, MIP-1A were significantly higher in 2019-nCoV infected patients in ICU than those in non-ICU  
179 patients, and the incidence of ARDS, secondary infection, shock, acute heart, and kidney injury was  
180 significantly higher in patients with ICU than in non-ICU patients. The results of this study indicated  
181 that 21 patients in the severe group had IL-4, IL-10, IL-17, and TNF within normal values. TNF and  
182 IFN mainly secreted by Th1 cells and NK cells were not significantly different between the mild  
183 and severe groups. In the mild group, 55.88% of the patients had IL-6 detection value of 0, and  
184 30.39% of the patients had IL-6 detection value higher than the normal value. The reason remains  
185 to be elucidated, which may be related to the inhibition of Th2 cells involved in humoral immunity  
186 in the early stage of infection. However, the proportion of IL-6 above normal was 76.19% in the  
187 severe group, which was significantly higher than that in the mild group. This is in line with the  
188 concept of "Cytokine Storm", which must be experienced by patients with mild illness to become  
189 severe, emphasized by Lanjuan Li, an academician of the Chinese Academy of Engineering. In  
190 addition, in the course of diagnosis and treatment, the Chongqing Three Gorges Central Hospital  
191 noticed that monitoring the changes of cytokines during the treatment process is of certain  
192 significance to optimize the treatment plan and predict the outcome of the disease.

193 The results of this study suggested that there was no significant linear correlation between  
194 lymphocyte subsets and cytokines. By analyzing the differences of lymphocyte subsets and  
195 cytokines in peripheral blood between the mild and severe patients, we found that only CD4 + T,  
196 CD8 + T, IL-6, IL-10 had statistical significance between the mild and severe groups, suggesting  
197 that the immunosuppression of severe patients with 2019-nCoV infection was more obvious, which  
198 was consistent with the opinions of many experts.<sup>5, 6</sup> For several results of this study, for example,  
199 the proportion of patients with an IL-6 value of 0 in the mild group was as high as 55.88%, there  
200 was no significant difference in terms of IL-17, TNF, IFN, and IL-4 between the two groups of  
201 patients, both B cell and NK cell decreased in different degrees in two groups of patients, the  
202 possible reasons are as follows. (1)The conclusion of this study is a true reflection of the  
203 characteristics of 2019-nCoV itself; (2) In the early stage of 2019-nCoV infection, due to the strong  
204 variability and good concealment of the virus, it cannot be quickly recognized by the body; (3)  
205 2019-nCoV releases certain special factors after entering the body and interferes with the body's

206 initiation of a specific immune response; (4) Other reasons that have not yet been confirmed.

207 This study has several limitations. Firstly, as the largest diagnosis and treatment center for  
208 patients with NCP in Chongqing area, our hospital has more than 123 patients so far. The sample  
209 size was relatively small compared with Wuhan, where the disease originated, which may have some  
210 impact on the statistical results. But on the whole, the number of patients in this area was in the  
211 middle level for other parts of the country except Wuhan, and the research results were relatively  
212 reliable. Secondly, the humoral immunity level of the included patients was not monitored, so there  
213 was a certain deficiency in the evaluation of the immune system. Thirdly, due to the large-scale  
214 outbreak of the epidemic restricting the flow of people, data on healthy patients are lacking as blank  
215 controls.

216 In future studies, data will be collected from healthy patients as blank controls to further  
217 explore the predictive value of peripheral blood lymphocyte subsets and cytokines for patients with  
218 2019-nCoV infection. At the same time, we will cooperate with other designated treatment units to  
219 carry out multicenter research to include more confirmed 2019-nCoV infected patients, expand the  
220 sample size, and design more rigorous randomized controlled trials. In addition, we will strengthen  
221 the follow-up of patients who are cured and discharged, and regularly detect the patient's peripheral  
222 blood lymphocyte subsets and cytokines.

223

#### 224 **Acknowledgement**

225 We sincerely thank Lian Guo, director of the Teaching Department of the Chongqing Three Gorges  
226 Central Hospital, and Chunhui Lang, director of the Foreign Affairs Department of Scientific  
227 Research, for their great support to this subject.

228

#### 229 **Funding**

230 Project No.2020CDJGRH-YJ03 supported by the Fundamental Research Funds for the Central  
231 Universities.

232

#### 233 **Data availability**

234 The datasets generated and analyzed during the current study are available from the corresponding  
235 author on reasonable request.

236

### 237 **Competing Interest Statement**

238 The authors have declared no competing interest.

239

### 240 **Author Contribution**

241 J.L. had the idea for and designed the study and had full access to all data in the study and take  
242 responsibility for the integrity of the data and the accuracy of the data analysis. S.W., S.F., X.Z.,  
243 Q.X., K.X., J.X., B.Z. and Y.C. contributed to writing of the report. L.G. and C.L. contributed to  
244 critical revision of the report. Q.Y., Z.Y. and M.Q. contributed to the statistical analysis. All authors  
245 contributed to data acquisition, data analysis, or data interpretation, and reviewed and approved the  
246 final version.

247

248 **References**

- 249 1. Michelle L. Holshue, M.P.H., Chas DeBolt, M.P.H., S, et.al. First Case of 2019 Novel  
250 Coronavirus in the United States. The new england journal of medicine, January 31, 2020, at  
251 NEJM.org. DOI: 10.1056/NEJMoa2001191.
- 252 2. Huabiao Chen. Study on immune response of SARS coronavirus-specific cytotoxic T  
253 lymphocytes. Second Military Medical University, 2005: 1-95.
- 254 3. Kun Xue. Effect of atypical influenza virus infection on NK cell activity [D]. China Medical  
255 University, 2014.
- 256 4. Chaolin Huang, Yeming Wang, Xingwang Li, et.al. Clinical features of patients infected with  
257 2019 novel coronavirus in Wuhan, China.The lancet, Published online January 24, 2020.  
258 Doi:10.1016/S0140-6736(20)30183-5.
- 259 5. Diagnosis and treatment of pneumonia with a new coronavirus infection (trial version 5).
- 260 6. Beijing Union Medical College Hospital on the "new coronavirus infected pneumonia"  
261 treatment proposal (V2.0)
- 262

263 **Tables**

264 **Table 1.** Distribution of lymphocyte subsets in peripheral blood of 123 patients with novel  
265 coronavirus (2019-nCoV) pneumonia (NCP)

groups	groups	CD4 <sup>+</sup> T	CD8 <sup>+</sup> T	B Cell	NK Cell	CD4 <sup>+</sup> T / CD8 <sup>+</sup> T
Mild group	below normal values (n, %)	54(52.90)	29(28.40)	26(25.49)	35(34.31)	3(2.94)
	within normal values (n, %)	48(47.10)	73(71.60)	75(73.50)	66(64.71)	95(93.14)
	above normal values (n, %)	-	-	1(0.01)	1(0.01)	4(3.92)
severe group	below normal values (n, %)	20(95.24)	13(61.90)	6(28.57)	10(47.62)	2(9.53)
	within normal values (n, %)	1(4.76)	8(38.10)	15(71.43)	11(52.38)	18(85.71)
	above normal values (n, %)	-	-	-	-	1(4.76)

266

267 **Table 2.** Cytokines status in peripheral blood of 123 patients with novel coronavirus (2019-nCoV)  
268 pneumonia (NCP)

groups	groups	IL-4	IL-6	IL-10	IL-17	TNF	IFN
Mild group	0 (n, %)	-	57(55.88)	-	-	-	5(4.90)
	within normal values (n, %)	102(100.00)	14(13.73)	102(100.00)	102(100.00)	100(98.04)	92(90.20)
	above normal values (n, %)	-	31(30.39)	-	-	2(1.96)	5(4.90)
severe group	0 (n, %)	-	3(14.29)	-	-	-	-
	within normal values (n, %)	21(100.00)	2(9.52)	21(100.00)	21(100.00)	21(100.00)	20(95.24)
	above normal values (n, %)	-	16(76.19)	-	-	-	1(4.76)

269

270 **Table 3.** Correlation analysis between IL-6 and peripheral blood lymphocytes

the Mild group (n=45)					
lymphocyte subsets	CD4 <sup>+</sup> T	CD8 <sup>+</sup> T	B Cell	NK Cell	CD4 <sup>+</sup> T / CD8 <sup>+</sup> T
r <sup>2</sup>	0.00000325	0.00098	0.0025	0.0022	0.0003
the severe group (n=18)					
lymphocyte subsets	CD4 <sup>+</sup> T	CD8 <sup>+</sup> T	B Cell	NK Cell	CD4 <sup>+</sup> T / CD8 <sup>+</sup> T
r <sup>2</sup>	0.04561	0.0445	0.05237	0.0005074	0.05673

271

272

273

274

275

276

277

278 **Table 4.** Comparison of lymphocyte subsets and cytokines in peripheral blood between mild and  
 279 severe patients

	the Mild group		the severe group		<i>P</i>
	n	$\bar{x} \pm s$	n	$\bar{x} \pm s$	
CD4 <sup>+</sup> T	102	451.3 ± 23.0	21	263.2 ± 28.83	0.0005
CD8 <sup>+</sup> T	102	288.6 ± 14.23	21	179 ± 23.87	0.0013
B Cell	102	166 ± 11.98	21	125.3 ± 13.49	0.1375
NK Cell	102	147 ± 10.36	21	119.6 ± 16.5	0.258
CD4 <sup>+</sup> T/CD8 <sup>+</sup> T	102	1.671 ± 0.05941	21	1.509 ± 0.1701	0.2857
IL-4	102	1.69 ± 0.07049	21	1.83 ± 0.1849	0.4317
IL-6	45	13.41 ± 1.84	18	37.77 ± 7.801	<0.0001
IL-10	102	2.464 ± 0.08506	21	4.59 ± 0.3777	<0.0001
IL-17	102	1.095 ± 0.02265	21	1.16 ± 0.05711	0.2463
TNF	102	4.077 ± 1.588	21	2.948 ± 0.4432,	0.7486
IFN	97	5.132 ± 0.8413	21	6.904 ± 1.247	0.3533

280